VEGFA and pleural mesothelioma: The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) demonstrated the benefit of adding bevacizumab (a full-length recombinant humanized monoclonal antibody targeting VEGF) to cisplatin/pemetrexed chemotherapy, improving both overall survival (OS) and progression-free survival (PFS) in 448 patients with pleural mesothelioma (PM) [3,4].